Watermark

BGB-16673-303

Not yet recruiting

A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Ask to Join

BeOne Study ID info

BGB-16673-303

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents